The insider sales are routine post-grant liquidity events and not a standalone bearish signal. However, the $400M shelf registration and going-concern warning create acute financing risk. Monitor for an ATM drawdown or equity offering in the coming weeks, which would be highly dilutive. The Phase 3 XPORT-EC-042 endometrial cancer trial enrollment completion is a binary catalyst but does not address near-term cash needs.
KPTI drugs
KPTI drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 18 $7.14entry
- T+1 · 6mo ago +4.62%α +5.27% · $7.47
- T+5 · 6mo ago +25.63%α +24.01% · $8.97
- T+20 · 5mo ago +27.45%α +25.87% · $9.10
- T+60 · 3mo ago −71.57%α −76.42% · $2.03
Price Chart
How similar events traded
Executive Summary
Six Karyopharm executives, including the CEO and C-suite, sold a total of $35K in open-market shares on May 14, 2026, one day after receiving equity grants and one day after the company reported Q1 2026 earnings. The sales are trivial relative to the $201M market cap (0.017%) and coincide with a $400M shelf registration filed 10 days prior, a going-concern warning, and cash runway extending only into late Q3 2026. The cluster is likely liquidity-driven following vesting/grant events rather than a coordinated bearish signal, but the broader capital structure risk is material.
Key Financial Metrics
Key Facts
- Six insiders sold $35K in open-market shares on May 14, 2026, representing 0.017% of market cap
- CEO Richard Paulson sold $21K (2,203 shares at $9.50), the largest sale in the cluster
- All six insiders received equity grants on May 13, 2026 (non-cash, $0 value), followed by sales the next day
- Q1 2026 revenue of $35.1M (up 17% YoY) beat consensus EPS of -$1.44 by 29%, but net loss was $22.4M
- Phase 3 SENTRY myelofibrosis trial missed its second co-primary endpoint (symptom score)
- $400M universal shelf registration (including $100M ATM) filed May 4, representing ~200% of market cap
- Auditor raised substantial doubt about going concern; cash runway extends only into late Q3 2026
- RA Capital shelf registration for 8.8M shares (resale, no proceeds to company) also filed May 4
Financial Impact
Insider sales of $35K are immaterial (0.017% of $201M market cap), but the $400M shelf registration represents potential dilution of ~200% of market cap
Risk Factors
- Massive dilution from $400M shelf registration (200% of market cap) if drawn down
- Cash runway only into late Q3 2026, likely need for dilutive financing before then
- Phase 3 SENTRY trial missed second co-primary endpoint, raising pipeline uncertainty
- Going-concern warning from auditor signals potential bankruptcy risk without capital infusion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KPTI-1778876069336 |
Track record
30 reports on KPTI
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers